United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

ipsen ltd - cabozantinib s-malate - tablet - 40mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

ipsen ltd - cabozantinib s-malate - tablet - 60mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

ipsen ltd - triptorelin - powder and solvent for suspension for injection - 11.25mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

ipsen ltd - telotristat ethyl - tablet - 250mg

Ireland - English - HPRA (Health Products Regulatory Authority)

ipsen pharma - clostridium botulinum toxin type a haemagglutinin complex - powder for solution for injection - 125 speywood - other muscle relaxants, peripherally acting agents; botulinum toxin

New Zealand - English - Medsafe (Medicines Safety Authority)

servier laboratories nz ltd - irinotecan hydrochloride trihydrate 5 mg/ml (equiv 4.3 mg/ml irinotecan (anhydrous free base));   - concentrate for infusion - 43 mg/10ml - active: irinotecan hydrochloride trihydrate 5 mg/ml (equiv 4.3 mg/ml irinotecan (anhydrous free base))   excipient: 1,2-distearoyl-sn-glycero-3-phosphocholine cholesterol hepes n-(carbonyl-methoxypolyethylene glycol 2000)-1,2-distearoyl-sn-glycero-3-phosphoethanolamine sodium chloride sucrosofate water for injection - treatment of metastatic adenocarcinoma of the pancreas in combination with 5-fluorouracil and folinic acid (leucovorin) in adult patients who have been previously treated with gemcitabine

Ireland - English - HPRA (Health Products Regulatory Authority)

ipsen consumer healthcare - macrogol 4000 - powder for oral solution in sachet - 10 gram(s) - osmotically acting laxatives; macrogol

European Union - English - EMA (European Medicines Agency)

ipsen pharma - mecasermin - laron syndrome - pituitary and hypothalamic hormones and analogues - for the long-term treatment of growth failure in children and adolescents with severe primary insulin-like-growth-factor-1 deficiency (primary igfd).severe primary igfd is defined by:height standard deviation score ≤ -3.0 and;basal insulin-like growth factor-1 (igf-1) levels below the 2.5th percentile for age and gender and;growth hormone (gh) sufficiency;exclusion of secondary forms of igf-1 deficiency, such as malnutrition, hypothyroidism, or chronic treatment with pharmacologic doses of anti-inflammatory steroids.severe primary igfd includes patients with mutations in the gh receptor (ghr), post-ghr signalling pathway, and igf-1 gene defects; they are not gh deficient, and therefore, they cannot be expected to respond adequately to exogenous gh treatment. it is recommended to confirm the diagnosis by conducting an igf-1 generation test.

Ireland - English - HPRA (Health Products Regulatory Authority)

ipsen pharma - botulinum toxin a - haemagglutinin complex - solution for injection - 200 unit(s)/millilitre - botulinum toxin

Malta - English - Medicines Authority

ipsen pharma 65 quai georges gorse, 92100 boulogne-billancourt,, france - solution for injection - botulinum toxin type a 125 u/ml - muscle relaxants